TCM
SPRY icon

Tang Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Tang Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-409,463
Closed -$2.24M – 126
2023
Q4 		$2.24M Hold
409,463
– – 0.21% 88
2023
Q3 		$1.55M Hold
409,463
– – 0.22% 81
2023
Q2 		$2.74M Hold
409,463
– – 0.4% 61
2023
Q1 		$2.67M Hold
409,463
– – 0.4% 60
2022
Q4 		$3.49M Hold
409,463
– – 0.51% 47
2022
Q3 		$2.16M Buy
+409,463
New +$2.02M 0.27% 69

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tang Capital Management's SPRY Position: Q1 2024 in Review

Tang Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 409,463 shares — an estimated $2.24M sold.

Tang Capital Management first reported a position in SPRY in Q3 2022 and held it in 6 quarters. The position peaked at $3.49M in Q4 2022. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Tang Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 409,463 ARS Pharmaceuticals shares in Q1 2024, an estimated $2.24M.
  • Tang Capital Management first reported a position in ARS Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Tang Capital Management's ARS Pharmaceuticals position peaked at $3.49M in Q4 2022.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.